Düsseldorf, Germany, 17 November 2026 — Amoy Diagnostics Co., Ltd. (AmoyDx) hosted its 2026 Distributors Annual Meeting at NH Düsseldorf City, with distributors and partners attending in person and online. The program covered medical and product developments in precision oncology, regulatory strategy, marketing plans for 2027, applications and technical support, and collaborations with pharmaceutical companies.
Long-term partnerships with distributors are central to AmoyDx’s international business strategy. In 2027, the company will continue to invest in international markets and support its distributors with product registration, marketing and technical services that address local business needs.
AmoyDx will further develop its PCR and next-generation sequencing (NGS) portfolios and expand its automation capabilities. By integrating reagents, instruments, testing workflows and technical support, the company aims to help distributors deliver end-to-end testing solutions to local laboratories.
Regulatory priorities include continued work under the European Union’s In Vitro Diagnostic Medical Devices Regulation (IVDR) and product registration in Japan and other key markets. AmoyDx will also deepen its collaborations with pharmaceutical companies to advance the development and commercialization of companion diagnostics.Feedback from distributors on local market needs will continue to guide AmoyDx’s work with its partners as they bring precision oncology diagnostics into clinical use in more markets.
AmoyDx will continue to work closely with its distributors to expand its international presence and bring precision oncology diagnostics to clinical laboratories in more markets.
.png)
Long-term partnerships with distributors are central to AmoyDx’s international business strategy. In 2027, the company will continue to invest in international markets and support its distributors with product registration, marketing and technical services that address local business needs.
AmoyDx will further develop its PCR and next-generation sequencing (NGS) portfolios and expand its automation capabilities. By integrating reagents, instruments, testing workflows and technical support, the company aims to help distributors deliver end-to-end testing solutions to local laboratories.
Regulatory priorities include continued work under the European Union’s In Vitro Diagnostic Medical Devices Regulation (IVDR) and product registration in Japan and other key markets. AmoyDx will also deepen its collaborations with pharmaceutical companies to advance the development and commercialization of companion diagnostics.Feedback from distributors on local market needs will continue to guide AmoyDx’s work with its partners as they bring precision oncology diagnostics into clinical use in more markets.
AmoyDx will continue to work closely with its distributors to expand its international presence and bring precision oncology diagnostics to clinical laboratories in more markets.
.png)
TÜV SÜD Officially Presents IVDR Companion Diagnostic Certificate to Amoy Diagnostics
Next
Subscribe
to our
newsletter